Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | KHK | P50053 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR1D | P28221 | 2/20 | 0.30 |
| ▸ | HTR1B | P28222 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160670 | 0.92 | DDB1 (0.34) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL30990746 | 0.89 | DDB1 (0.32) | DDB1CRBN | |
| SCHEMBL31160806 | 0.89 | DDB1 (0.34) | DDB1CRBN | |
| SCHEMBL30990663 | 0.88 | DDB1 (0.31) | DDB1CRBN | |
| SCHEMBL31731167 | 0.88 | DDB1 (0.39) | DDB1CRBNHTR6DRD2SLC6A4 | |
| SCHEMBL30990665 | 0.85 | DDB1 (0.37) | DDB1CRBN | |
| SCHEMBL31731259 | 0.84 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31160705 | 0.84 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL31731245 | 0.84 | DDB1 (0.36) | DDB1CRBNDRD2SLC6A4 | |
| SCHEMBL30990736 | 0.83 | DDB1 (0.32) | DDB1CRBNHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173412-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | DDB1 270/4885CRBN 277/4885HTR6 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.